Skip to content
Facebook Twitter Linkedin
InMed-logo-01
  • Pharmaceutical
    • Cannabinoids in Development
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Neurodegenerative Disease
    • Novel Cannabinoid Analogs
  • Manufacturing
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
    • BayMedica Cannabinoid Biosynthesis
    • Rare Cannabinoid Ingredients
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos
Menu
  • Pharmaceutical
    • Cannabinoids in Development
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Neurodegenerative Disease
    • Novel Cannabinoid Analogs
  • Manufacturing
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
    • BayMedica Cannabinoid Biosynthesis
    • Rare Cannabinoid Ingredients
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos

InMed Conferences and Events

Upcoming Events

Past Events

VirtualInvestorConferences.com – Life Sciences Investor Forum

Date: March 9, 2023

Time: 11:00am ET

VirtualInvestorConferences.com – Life Sciences Investor Forum

InMed’s CEO, Mr Eric A. Adams, will perform a presentation followed by a questions and answers session. Management will be available for virtual one-on-one meetings with institutional and individual investors from March 9 – March 14.

Registration: https://bit.ly/3IoXpvP

Learn more about the event at www.virtualinvestorconferences.com

Add to Calendar

Emerging Growth Conference

Date: March 8, 2023

Time: 12:30pm ET

Emerging Growth Conference

InMed’s CEO, Mr. Eric A. Adams, will perform a presentation followed by a questions and answers session. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available on EmergingGrowth.com and on the Emerging Growth YouTube Channel.

Watch the presentation here on demand

 

Add to Calendar

Tribe Public’s Webinar Event “Exploring the Neuroprotective Qualities of Rare Cannabinoids”

Date: November 17, 2022

Time: 8am PT / 11am ET

Registration Now Open For Tribe Public’s Webinar Event “Exploring the Neuroprotective Qualities of Rare Cannabinoids” Featuring InMed’s Management Team On November 17, 2022

Meet with InMed’s President and CEO Eric A. Adams and Eric Hsu, SVP of Preclinical Research and Development.

Date: November 17, 2022
Time: 8:00am PST / 11:00am EST

To register to join the complimentary, ZOOM webinar-based event, please visit Tribe Public LLC at INMNOV17.TribePublic.com. Once registered, participants may begin forwarding their questions for InMed’s  management to Tribe Public at [email protected] or share their questions via the ZOOM chat feature during the event. Tribe Public’s Managing Member, John F. Heerdink, Jr., will host the event and relay all questions to management.

Add to Calendar

Force For Knowledge Cannabis Symposium – Jump Starting Cannabis Valuations 101

Date: June 29, 2022

Time: 12:00pm ET

Dr. Shane Johnson, GM and SVP of BayMedica, InMed’s subsidiary, will be joining the panel presentation “The Intersection Between Medical and Health & Wellness” with Radicle Science’s Dr. Jeff Chen.

A discussion of the opportunities in pharmaceutical industry in addition to current health & wellness uses.

  • Shane Johnson, SVP, BayMedica a Division of InMed Pharmaceuticals
  • Jeff Chen, MD & MBA, CEO & Co-founder, Radicle Science

RSVP at : https://forcefamilyoffice.com/events/technology/2022-06-22-force-knowledge-cannabis/

Add to Calendar

H.C. Wainwright Global Investment Conference

Date: May 23-26, 2022

Presentation: The webcast recording will available on this page. Please check back for the link to access the webcast.

Management will be available for virtual one-on-one meetings with institutional and corporate clients of the firm. To request 1-on-1 meetings with the Company, please contact your H.C. Wainwright institutional representative.

More information about the H.C. Wainwright Global Investment Conference can be found here.

Add to Calendar

Canaccord Genuity’s 6th Annual Global Cannabis Conference

Date: May 11, 2022

Presentation: The webcast recording will be posted on this page. Check back for the link.

Management will be available for virtual one-on-one meetings with institutional and corporate clients of the firm. To request 1-on-1 meetings with the Company, please contact your Canaccord institutional representative. More information on the Canaccord Cannabis Conference can be found here.

Add to Calendar

Benzinga Spring 2022 Cannabis Capital Conference

Date: April 20-21, 2022

Management will be available for virtual one-on-one meetings with institutions and industry representatives. To request 1-on-1 meetings with the Company please contact investor relations at [email protected]

Add to Calendar

InMed Presenting at 34th Annual Roth Conference

Date: March 13-15, 2022

InMed Pharmaceuticals will be presenting at the upcoming 34th Annual Roth Conference in Orange Country, CA March 13-15, 2022.

Watch the fireside chat with InMed CEO, Eric A. Adams and Roth Analyst Scott Henry:

https://wsw.com/webcast/roth43/inm2/1748056

InMed Presentation webcast link: https://wsw.com/webcast/roth43/inm/1677456

Roth Conference website

Add to Calendar

Conference Call and Webcast: InMed’s Second Quarter Fiscal 2022 Financial Results and Business Update

Date: Tuesday, February 15, 2022

Time: 11:00am PT / 2:00pm ET

Conference Call & Webcast*:

Tuesday, February 15, 2022, at 11:00 AM Pacific Time, 02:00 PM Eastern Time
US/CANADA Participant Toll-Free Dial-In Number: +1 (855) 605-1745
US/CANADA Participant International Dial-In Number: +1 (914) 987-7959
Conference ID: 8645175
Webcast: https://edge.media-server.com/mmc/p/sa6ykfmv
(*Webcast replay available for 90 days)

The Company’s full financial statements and related MD&A for the second quarter of fiscal year 2022, ended December 31, 2021 will be available at www.inmedpharma.com, www.sedar.com  and at www.sec.gov on February 15, 2022.

Add to Calendar

InMed presenting at the KCSA Cannabis Virtual Investor Conference

Date: Thursday, January 20, 2022

Time: 1:30pm ET

InMed presenting at the KCSA Cannabis Virtual Investor Conference this Thursday at 1:30pm ET. President and CEO, Eric A. Adams to present.

Register free to participate. https://www.virtualinvestorconferences.com/events/event-details/kcsa-cannabis-virtual-investor-conference-0?utm_source=Virtual+Investor+Conference

Add to Calendar
Load More


INM-755

A cannabinol (CBN) topical cream in Phase 2 clinical trials for epidermolysis bullosa
Learn More

INM-088

A cannabinol (CBN) formulation in preclinical development for the treatment of glaucoma
Learn More
InMed-logo-mono
#310 – 815 West Hastings St.
Vancouver, BC, Canada
V6C 1B4

Pharmaceutical

  • Cannabinoids in Development
  • INM-755 for Epidermolysis Bullosa
  • INM-088 for Glaucoma
  • Neurodegenerative Disease
  • Novel Cannabinoid Analogs

MANUFACTURING

  • Cannabinoid Manufacturing Expertise
  • IntegraSyn™ Cannabinoid Manufacturing
  • BayMedica Cannabinoid Biosynthesis
  • Rare Cannabinoid Ingredients

Investor

  • News
  • Events
  • Stock Information
  • Corporate Governance
  • Financials & AGM
  • Filings
  • Presentations
  • Media

CORPORATE

  • Management
  • Board of Directors
  • Scientific Advisory Board
  • Partners and Collaborators
  • Careers
  • Contact

Learn

  • What is Cannabinol (CBN)?
  • What is Epidermolysis Bullosa (EB)?
  • What is Glaucoma?
  • Cannabinoid Manufacturing Economics 101
  • GMP Manufacturing Standards by Product Type
  • Cannabinoids for Glaucoma
  • Cannabinoid Science
  • Articles and Videos

© Copyright 2023 InMed Pharmaceuticals Inc.

  • Privacy Policy
  • Terms of Use
  • Legal Disclaimer
  • Find Us On:
Subscribe

Sign up to receive emails from InMed Pharmaceuticals

"*" indicates required fields

Name*
Consent